Britain and America have agreed to a major trade agreement that will maintain no import taxes on UK medicine products going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to increase funding on drugs through the NHS. This commitment guarantees that duties on these vital exports will remain at zero for a duration of the next three years.
This deal comes after previous warnings to hike duties on branded pharmaceutical imports, with potential rates mentioned up to 100%.
"This agreement between the UK reinforces the global environment for cutting-edge drugs and brings much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Importance
Medicines are one of the Britain's largest goods shipped to the US, which is by far the primary buyer for leading UK drugmakers.
Statistics reveal that in the one-year period to the end of September, the UK exported drugs valued at over eleven billion pounds to the US. This value accounted for a significant portion of all goods exports in that period.
"This agreement secures jobs, increases investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Specific British Pledges
The deal includes several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be capped at 15%. In the past, refunds were more than 20%.
Broader Context
This agreement takes place against a ongoing tension between the sector and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by arguments that American consumers were paying several times more for the identical medicines than consumers in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the last ten years.
